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Abstract
Background. There is a need for reliable prognostic parameters in pulmonary arterial hyper-
tension (PAH), especially in children. Pulsatile components of the right ventricular afterload, 
represented by pulmonary arterial compliance (PACi) and pulmonary stroke volume (PSVi), 
may provide important additional prognostic information to conventional static haemody-
namic parameters. The aim of this study was to determine the prognostic value of PACi and 
PSVi in paediatric PAH.
Methods. Right heart catheterization data of 52 consecutive paediatric idiopathic/hereditary 
PAH and PAH associated with congenital heart disease patients with full haemodynamic 
evaluation seen at the Dutch national referral centre for paediatric pulmonary hypertension 
between 1993 and 2010 were reviewed. A control group was composed of patients with nor-
mal pulmonary vascular resistance. PSVi and PACi were calculated and tested for predictive 
value for transplant-free survival.
Results. PAH patients had significantly lower PSVi and PACi compared to control patients. 
PSVi and PACi were lower in patients with higher WHO-functional class compared to those 
with lower functional classes. Higher PSVi, PACi and mSAP and lower mPAP/mSAP and heart 
rate were associated with improved survival, independent from WHO-functional class and 
PAH-targeted therapy. In multivariate analyses PSVi, heart rate and mSAP emerged as the 
strongest haemodynamic predictors of survival. The effect of vasodilator challenge on the 
haemodynamic variables did not provide additional prognostic information.
Conclusions. The parameters of both the pulsatile and static pulmonary circulations are 
strong independent predictors for transplant-free survival, and therefore can be of comple-
mentary value in assessing disease severity, predicting survival and guiding treatment in 
paediatric PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is a disease characterized by pulmonary vascular 
remodelling, leading to severe elevation of right ventricular afterload, ultimately resulting 
in right ventricular (RV) failure and death. Despite emerging treatment options, PAH is a 
progressive disease and data on its diagnosis, treatment and outcome is limited, especially 
in children.1 In PAH, treatment decisions are based on the assessment of disease severity and 
prognosis by the use of prognostic (surrogate-) parameters.2,3
There is a strong need for reliable prognostic parameters that can be used as clinical endpoints 
in order to guide the treatment of PAH. The currently used parameters are far from perfect, 
especially in young children with PAH. The World Health Organization functional class (WHO-
functional class) and 6-minute walk distance (6-MWD) are recognized as valuable prognostic 
parameters that are recommended to be used in goal-oriented treatment strategies in adult 
PAH-patients.4-7 In children, however, both parameters are often less reliable or not feasible 
because of young age and/or impaired development.8 Haemodynamic parameters, such 
as pulmonary vascular resistance (PVR), and mean pulmonary arterial pressure (mPAP), are 
important objective measurements used to confirm the diagnosis of PAH. Furthermore, they 
may provide prognostic information. However, while invasive haemodynamic evaluation in 
children frequently requires general anaesthesia, the correlation of mPAP and PVRi with clini-
cal status and survival is limited.5,9-14
Elevated RV afterload leading to RV failure is the main determinant of mortality in PAH. 
RV afterload consists of static components (PVR and mPAP) defining net forward ﬂow, and 
pulsatile components defining ﬂow and pressure oscillations. Pulsatile components include 
pulmonary arterial compliance (PAC), the ability of pulmonary arteries to accommodate 
oscillatory changes in volume, and pulmonary stroke volume (PSV), the amount of blood 
ejected in the pulmonary artery per cardiac cycle. The latter differs from RV stroke volume 
in the setting of intracardiac shunt or tricuspid regurgitation. Conventional haemodynamic 
parameters such as mPAP and PVRi only partially represent RV afterload, since they represent 
its static components and ignore its pulsatile components.9,15 In healthy subjects the pul-
satile components contribute little to the RV afterload, due to the low resistance and high 
compliance of the pulmonary circulation. However in PAH their contribution to RV afterload 
becomes increasingly important due to arterial stiffening and increased reﬂection waves.16,17 
PAC and PSV, both reﬂecting pulsatile components of the RV afterload, may therefore provide 
additional prognostic information in PAH.
Previous findings in adult PAH patients indicated that PAC and PSV may be valuable predic-
tors for prognosis in adult PAH.18-21 In paediatric PAH, PAC has previously been shown to be 
associated with pulmonary vascular disease severity, however its prognostic value for mortal-
ity is not clear.22-24 The purpose of this study was to determine the prognostic value of PSV 
and PAC in children with idiopathic/hereditary PAH (IPAH/HPAH) and PAH associated with 
congenital heart disease (PAH-CHD).
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Methods
In the Netherlands, all paediatric PAH patients are referred to the University Medical Centre Gron-
ingen, the national referral centre within the Dutch National Network for Paediatric Pulmonary 
Hypertension. At the referral centre, the diagnosis of PAH is confirmed by heart catheterization, 
treatment strategies have evolved according to the ‘ESC guidelines for the diagnosis and treat-
ment of PAH’, and all patients are regularly seen at standardized follow-up visits.2
We retrospectively reviewed the diagnostic heart catheterization data of all paediatric patients 
with IPAH/HPAH and PAH-CHD seen at the Dutch national referral centre from 1993 to 2010. PAH 
was defined as elevated mPAP ≥ 25 mmHg at rest, with a pulmonary capillary wedge pressure 
(mPCWP) ≤ 15 mmHg and elevated PVRi ≥ 3 Wood units · m2 measured during heart catheter-
ization. Only patients who had a full baseline haemodynamic assessment by heart catheteriza-
tion were included in the study. PAH-CHD patients were subdivided into three different groups, 
based on their circulatory physiology: 1) patients with an unrestricted pre-tricuspid shunt 
(atrial septal defects); 2) patients with an unrestricted post-tricuspid shunt ([atrio]ventricular 
septal defects, patent ductus arteriosus, or uncorrected univentricular heart with unobstructed 
pulmonary blood ﬂow) and 3) patients with surgically corrected post-tricuspid shunt (without 
residual shunts) in whom PAH developed or persisted after shunt-closure.
A control group, which was age- and shunt-matched in order to rule out both age and circula-
tory physiology as possible confounding factors, was composed of patients with low pul-
monary vascular resistance (PVRi<2.5 WU.m2), catheterized at the University Medical Centre 
Groningen. The control group included control patients with normal pulmonary circulation 
(patients with aortic stenosis) and shunt control patients with increased pulmonary blood 
ﬂow index (Qpi/Qsi > 1.2) due to persistent ductus arteriosus, or atrial septal defects, with 
normal mPAP (<20 mmHg).
Our institutional human research committee approved the protocol for the Dutch national 
clinical patient registry and the use of its data for observational studies. Patients or their legal 
guardians provided informed consent. The authors of this manuscript have certified that they 
comply with the Principles of Ethical Publishing in the International Journal of Cardiology.
Baseline evaluation
Baseline evaluation included WHO-functional class and diagnostic heart catheterization. Baseline 
haemodynamic measurements included mean right atrial pressure (mRAP), mPAP, pulmonary 
arterial pulse pressure (PP), mPCWP, PVR indexed for body surface area (PVRi), Qpi, pulmonary 
stroke volume index (PSVi) and pulmonary arterial compliance index (PACi). Qpi was determined 
by using Fick’s method, based on estimated oxygen consumption (VO2). VO2 was estimated by 
using two methods: (i) for patients < 7 years of age VO2 = 1.39 × Height(cm) + 0.84 × Weight(kg) 
− 35.7 and (ii) for patients > 7 years of age by the tables of Lafarge and Miettinen.25,26 PVRi was 
determined by dividing the pulmonary arterial to venous pressure fall by Qpi. The PSVi was de-
termined by dividing Qpi by the heart rate, and finally PACi was calculated by dividing PSVi by PP.
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During heart catheterization, acute vasodilator challenge was performed by using inhaled 
nitric oxide (NO), or NO with 100% O2. In the case of sequential pulmonary vasodilator re-
sponse tests with both conditions, the maximal response of each individual parameter was 
determined and used for analyses.
Statistical analyses
Data are presented as mean ± standard deviation, median (interquartile range) or number 
(percentage) of patients. Patient characteristics and baseline haemodynamic parameters 
were compared between PAH patients and controls and between IPAH/ HPAH and PAH-
CHD patients, by using t-test for normally distributed variables, Mann–Whitney U test for 
not-normally distributed data and Chi-square test for categorical variables. Analyses were 
performed by using SPSS 18.0 (SPSS Inc. Chicago, IL, USA) and Stata 11 (Statacorp, College 
Station, Texas, USA). The level of significance was set to 0.05.
Survival analyses were based on transplant-free survival from haemodynamic evaluation, 
with death and transplantation as end-points. Patients without end-point were censored at 
last follow-up visit. Survival was evaluated by using Kaplan–Meier curves and Log Rank tests. 
PACi, PSVi, mSAP and heart rate were split on their median for analyses with Kaplan–Meier 
curves. Subsequently, the correlation of continuous haemodynamic parameters and clinical 
parameters (WHO-class, diagnosis, shunt, age, therapy) with survival was evaluated by us-
ing Cox regression. Backward multivariate Cox regression was used to identify the strongest 
haemodynamic predictors for survival. In multivariate analyses the haemodynamic predic-
tors were corrected for clinical parameters that were associated with survival in univariate 
analyses. All variables met the proportionality assumptions and there were no statistical 
interactions between variables that were combined in multivariable analyses.
Results
Patient characteristics
Fifty-two paediatric PAH patients (31 female, 21 male) and 17 control patients (6 female and 
11 male) were included in this study. There were 32 IPAH/HPAH and 20 PAH-CHD patients (15 
with post-tricuspid shunt, 1 with pre-tricuspid shunt and 4 with corrected shunt). Median 
age of the PAH patients was 7.1 years. The distribution of gender, age and shunt types did not 
differ between the PAH patients and the control group (Table 1).
Patients were treated according to the evolving guidelines for diagnosis and treatment of 
pulmonary hypertension.2 Nine patients did not receive PAH-targeted therapy because they 
were diagnosed and died in the era in which PAH-targeted therapy (endothelin receptor 
antagonist, PDE5-inhibitor or prostacyclin derivate) was not yet available in the Netherlands. 
There were 23 patients on mono, and 20 patients on combination (dual or triple) PAH-
targeted therapy.
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Haemodynamics
The PAH patients had severe PAH with elevated mPAP and PVRi (Table 2). In contrast, control 
subjects without a pulmonary to systemic shunt had normal mPAP, PVRi and Qpi. Control 
subjects with a pre- or post-tricuspid shunt had increased Qpi (median 6.9 L/min/m2) due 
to left to right shunting, accompanied by a low PVRi (range 0.5–1.1 WU.m2) and normal 
mPAP (range 10–17 mmHg). The mSAP of the control patients was comparable to the PAH 
patients, reﬂecting a successful patient matching procedure. The PSVi and PACi were both 
significantly decreased in the PAH patients compared to the controls. Except for the aorta 
saturation, there were no significant differences in baseline haemodynamics between the 
IPAH/HPAH and PAH-CHD patients. Both PSVi and PACi were lower in patients with higher 
WHO-functional class (Figure 1).
41 (79%) PAH patients were tested for acute pulmonary vasodilator response. The mPAP, 
mPAP/mSAP and PVRi significantly decreased during acute vasodilator response (Table 3), 
whereas mean pulmonary arterial pulse pressure did not significantly change. Both PSVi and 
PACi increased significantly during acute vasodilator response testing.
Table 1 Baseline characteristics
All patients Control 
patients
P-value* IPAH/HPAP PAH-CHD P-value†
(n=52) (n=17) (n=32) (n=20)
Age at right heart 
catheterization (yrs)
7.1 (3.1;13.3) 7.1 (3.7;12.1) 0.99 7.6 (3.8;14.0) 7.0 (2.0;11.8) 0.27
Follow-up time (yrs) 3.9 (1.6;7.0) 3.7 (0.7;7.0) 4.1 (2.6;6.9) 0.73
Sex male 21 (40) 11 (65) 0.10 16 (50) 5 (25) 0.09
WHO-Functional class
I 1 (2) 0 (0) 1 (5) 0.82
II 17 (33) 12 (38) 5 (25)
III 26 (50) 15 (47) 11 (55)
IV 8 (15) 5 (16) 3 (15)
Shunt
No shunt 36 (69) 11 (65) 0.69 32 (100) 4 (20) <0.01‡
Pre-tricuspid shunt 1 (2) 1 (6) 1 (5)
Post-tricuspid shunt 15 (29) 5 (29) 15 (75)
Values are in median (interquartile range) or n (%) as appropriate. Comparison between *all patients versus 
control patients and †IPAH/HPAH versus PAH-CHD with Mann–Whitney U test, Chi-square tests or Fisher’s 
exact test as appropriate. IPAH/HPAH, idiopathic or hereditary pulmonary arterial hypertension; PAH-CHD, 
pulmonary arterial hypertension associated with congenital heart disease; yrs, years; WHO, World Health 
Organization.
‡Significant test result.
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Survival
The patients in our cohort had regular standardized follow-up visits, with a median follow-up 
time of 3.9 years (interquartile range 1.6–7.0 years). Considering the small number of patients 
with more than 7 years of follow-up (25%, 13 patients), survival analyses were truncated at 7 
years of follow-up. The 1-, 2-, and 5-year survival rates of the cohort were 88%, 86%, and 68%, 
respectively. No difference in survival between the iPAH/HPAH and PAH-CHD patient group 
could be demonstrated (Figure 2). Kaplan–Meier curves showed that a higher PSVi and a 
higher PACi were associated with better survival (Figure 3A). Furthermore, higher mSAP and 
lower heart rate were associated with improved survival (Figure 3B). The associations of PACi, 
PSVi, mSAP and heart rate with survival were not explained by differences in distribution of 
diagnosis, patients with HPAH or patients treated with prostacyclin derivate, between the 
percentile groups. Furthermore, there was no indication that the strength of these associa-
tions differed between the diagnosis subgroups.
In univariate Cox regression analyses higher PSVi, higher PACi, lower mPAP/mSAP, lower heart 
rate (during general anaesthesia) and higher mSAP were associated with better survival 
(Table 4). In contrast, mPAP, PVRI, Qpi and Qsi did not show a significant association with 
survival. In a backward stepwise multivariate Cox regression analysis including the haemo-
dynamic variables that were associated with survival in univariate analysis, PSVi, heart rate 
and mSAP emerged as the strongest haemodynamic predictors for survival in this series of 
paediatric PAH.
Patients in WHO-functional class IV had worse survival compared to patients in WHO-func-
tional classes I–III. Patients on PAH-targeted mono or combination therapy had better survival 



























I-II (n=18) III (n=26) IV (n=8) I-II (n=18) III (n=26) IV (n=8)
Scatter plot with indications of median and interquartile ranges of PSVi and PACi, respectively, for WHO-
functional class subgroups. P-values derived from Kruskal–Wallis test. PSVi, pulmonary stroke volume in-
dex; PACi, pulmonary arterial compliance index; WHO-functional class, World Health Organization func-
tional class.
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compared to patients for whom PAH-targeted therapy was not yet available. Therefore, sub-
sequently, haemodynamic variables that were demonstrated to have an association with sur-
vival were corrected for WHO-functional class and PAH-targeted therapy in multivariate Cox 
regression analyses. These analyses showed that higher PSVi, higher PACi, lower heart rate, 
Table 3 Acute vasodilator response test
IPAH/HPAH PAH-CHD All Patients P-value
(n=26) (n=15) (n=41)
mPAP Baseline 51 ± 21 51 ± 15 51  ± 19
Maximal change -5  ±  9 -1 ± 4 -3  ± 7
Maximal response 46 ± 21 50 ± 16 47  ± 19 <0.01*
mPAP/mSAP Baseline 0.8 ± 0.3 0.9  ± 0.2 0.9 ± 0.3
Maximal change -0.1 ± 0.2 -0.0  ± 0.1 -0.1 ± 0.2
Maximal response 0.7 ± 0.4 0.9  ± 0.2 0.8 ± 0.4 <0.01*
Qpi Baseline 2.5 (2.2;3.2) 2.7 (2.2;3.8) 2.6 (2.2;3.3)
Maximal change 0.2 (-0.0;0.7) 0.4 (-0.2;1.2) 0.2 (-0.0;0.7)
Maximal response 2.9 (2.2;3.9) 2.7 (2.2;4.9) 2.9 (2.2;4.1) <0.01*
Qsi Baseline 2.8 (2.3;3.3) 2.7 (2.3;4.2) 2.8 (2.3;3.8)
Maximal change 0.2 (-0.0;0.6) -0.4 (-0.6;-0.2) 0.0 (-0.3;0.3)
Maximal response 2.9 (2.3;3.9) 2.4 (2.2;3.6) 2.9 (2.3;3.7) 0.73
PVRi Baseline 14.8 (7.9;27.8) 15.7 (10.0;19.4) 15.7 (8.8;26.0)
Maximal change -3.0 (-4.9;-0.9) -1.7 (-6.3;0.4) -2.9 (-4.9;-0.9) 
Maximal response 10.1 (4.1;20.1) 14.8 (6.7;24.4) 11.7 (5.1;20.1) <0.01*
PVR/SVR Baseline 0.8 (0.5;1.1) 0.9 (0.6;1.4) 0.9 (0.5;1.1)
Maximal change -0.2 (-0.3;-0.1) -0.2 (-0.5;0.0) -0.2 (-0.3;-0.0)
Maximal response 0.6 (0.3;0.8) 0.6 (0.4;0.9) 0.6 (0.3;0.9) <0.01*
PSVi Baseline 32.5 (27.5;41.5) 30.4 (22.5;43.2) 32.0 (27.1;42.1)
Maximal change 4.8 (2.3;8.7) 6.1 (-0.2;12.7) 5.3 (2.2;9.9)
Maximal response 39.1 (33.2;52.3) 37.2 (26.5;46.5) 38.6 (31.3;48.4) <0.01*
PAPP Baseline 40  ± 14 38  ± 13 39  ± 14
Maximal change -3.7 ± 11.8 0.5 ± 4.5 -2.2 ± 9.9
Maximal response 36  ± 17 39  ± 12 37  ± 15 0.16
PACi Baseline 0.9 (0.6;1.1) 0.8 (0.6;1.3) 0.8 (0.6;1.1)
Maximal change 0.1 (0.1;0.5) 0.1 (-0.0;0.3) 0.1 (0.1;0.4)
Maximal response 1.0 (0.8;2.2) 0.9 (0.7;1.4) 1.0 (0.8;1.5) <0.01*
Values are in median (interquartile range) or mean ± SD as appropriate. Comparison between baseline and 
maximal vasodilator response in the all patients group with Wilcoxon Singed Rank Test or paired T-test as 
appropriate.
*Significant test result.
mPAP, mean pulmonary arterial pressure; mPAP/mSAP, mean pulmonary to systemic pressure ratio; Qpi, 
pulmonary flow index; Qsi, systemic flow index; PVRi, pulmonary vascular resistance index; PVR/SVR, pul-
monary to systemic vascular resistance ratio; PSVi, pulmonary stroke volume index; PAPP, pulmonary arte-
rial pulse pressure; PACi, pulmonary arterial compliance index.
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lower mPAP/mSAP and higher mSAP were associated with improved survival independent 
from WHO-functional class and PAH-targeted therapy (Table 4). Younger patients tended to 
have worse survival compared to older patients. In order to adjust the survival analysis for the 
effect of age on mSAP and heart rate, the multivariate analyses were additionally corrected 
for age (Table 4). After correction for age, the point estimates of the associations remained 
the same, indicating that the associations were independent from age.
Two of the IPAH/HPAH patients (6.3%) showed acute vasodilator response according to the 
response criteria of the ESC guidelines.2 Both patients survived during the study period and 
with that, responders tended to have improved survival compared to non-responders. How-
ever, individual haemodynamic variables during acute pulmonary vasodilator response test-
ing did not provide additional information to the prognostic value of their baseline values.
Discussion
Despite the introduction of PAH-targeted therapy, paediatric PAH is still a severe disease with 
a detrimental prognosis, illustrated by reported survival rates in the current era.11,13 Conven-
tional haemodynamic parameters represent only the static part of RV afterload and provide 
limited prognostic information. This study shows that pulsatile components of RV afterload 
provide important additional prognostic information.
The predictive value of PACi and PSVi for survival can be explained by their increasingly impor-
tant role in pulsatile ﬂow and RV afterload in PAH.16 High compliant pulmonary arteries can 
reduce pulmonary arterial pressures and ﬂow velocities, thereby delaying reﬂecting pressure 
waves. Reduced compliance leads to higher pressures, higher ﬂow rate and early reﬂection 
Figure 2: Survival of the study group.
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Kaplan–Meier curves showing the survival of all included PAH patients (left) and stratified for diagnosis 
subgroup (right). PAH, pulmonary arterial hypertension; PAH-CHD, pulmonary arterial hypertension associ-
ated with congenital heart disease; IPAH/HPAH, idiopathic or hereditary pulmonary arterial hypertension.
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waves, thereby increasing RV workload, which ultimately results in RV failure. Therefore in 
PAH, PACi reﬂects an important part of the RV afterload.
Since PACi and PVRi determine the ability of the pulmonary arteries to accommodate blood 
ﬂow, a reduced PACi and increased PVRi leads to reduced PSVi. Increased RV afterload and 
the accompanying increased RV work load and hypertrophy in PAH, may eventually decrease 
PSVi even further.27 One could question whether the association between PSVi and survival is 
driven by RV function or by progression of the pulmonary vascular disease. This is a complex 
Figure 3:
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26 20 18 13  9  6  5  3 
Patients at risk 
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26 19 17 15 10  7  6  5 
p=0.004 p=0.005 
PSVi > 32.9 ml/m2
PSVi < 32.9 ml/m2
PACi > 0.9 ml/mmHg/m2
PACi < 0.9 ml/mmHg/m2
Follow up time from heart catheterization (years)
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Patients at risk 
27 23 23 21 17 13 11  9 
25 17 15 12  9  6  6  4 
Patients at risk 
26 24 23 21 15 10  9  7 
26 16 15 12 11  9  8  6 
p=0.007 p=0.047 
mSAP > 60 mmHg
mSAP < 60 mmHg
HR < 79 beats/min
HR > 79 beats/min
A) Survival stratified for PSVi and PACi. Kaplan–Meier curves with log rank tests showing the survival of all 
included PAH patients stratified for the median of pulmonary stroke volume index (PSVi, left) and pulmo-
nary arterial compliance index (PACi, right). B) Survival stratified for mSAP and heart rate Kaplan–Meier 
curves with log rank tests showing the survival of all included PAH patients stratified for the median of 
mean systemic arterial pressure (mSAP, left) and heart rate (HR, right).
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issue, especially in a patient group with heterogeneous complex congenital heart diseases. 
The current data show that the association of PSVi with outcome was found not only in IPAH/
HPAH, but also in PAH-CHD patients with a shunt at post-tricuspid level. In the latter patient 
group, PSVi is not synonymous to RV stroke volume due to right to left shunting and thus 
PSVi does not simply reﬂect RV function. In patients with intracardiac shunts, PSVi was as-
sociated with survival. Furthermore, there was no indication that the strength of the found 
associations with survival in PAH-CHD patients differed from that in iPAH/HPAH patients. 
These findings support the notion that PSVi seems to represent a function of pulmonary 
vascular disease rather than of RV function.
PACi and PSVi both reﬂect disease severity in paediatric PAH. They are likely to decrease dur-
ing disease progression of PAH and are candidate-parameters to assess disease severity and 
treatment effects. PSVi may more fully represent the progression of the vascular disease than 
PACi, since PSVi is determined by the RV afterload as a whole, including vascular resistance, 
arterial compliance and reﬂection waves, whereas PACi predominantly represents pulmonary 
arterial compliance. This may explain why our analyses indicates that PSVi is the stronger 
prognostic parameter in paediatric PAH compared to PACi.
Higher PACi was associated with improved survival independent from WHO-functional 
class and therapy, which is in congruence with previous reports in adult PAH.18,19 Sajan et 
al.28 showed that in children with PAH, worse survival was predicted by either a higher or a 
lower than average PACi. In contrast, in the present study, the association between PACi and 
survival showed to be more linear. The reason for this disparity may lay in the difference in the 
composition of the study groups. Sajan et al.28 included a large group of PAH-CHD patients 
with high PACi and it was unclear whether these patients all had advanced, irreversible PAH, 
whereas in the current study, all PAH-CHD patients had advanced irreversible PAH.
Higher PSVi was associated with improved survival in our study. RV stroke volume measured 
by pulmonary arterial MRI or by Fick’s method has previously been shown to be a valuable 
prognostic factor in adult IPAH/HPAH.20 In earlier reports cardiac index has been shown to be 
a prognostic parameter in iPAH. However, PSVi showed to be a stronger predictor of survival 
in both paediatric and adult PAH.4,13,20 This can be explained by the fact that a decreased PSVi 
can be compensated by an increased heart rate, thereby maintaining cardiac output. The 
latter will affect the association of cardiac index with survival.20 This notion is supported by 
the association of higher heart rate with decreased survival as found in the current study.
The investigated patient cohort included patients for whom advanced PAH therapy was not 
yet available. Evolving treatment strategies may inﬂuence outcome and survival analyses. 
The analyses were corrected for this potentially confounding effect of treatment and the 
prognostic value of PACi and PSVi showed to be independent from treatment. This indicates 
that these associations were not affected by the evolving treatment strategies.
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In this study the conventional, static parameters mPAP and PVRi were not associated with 
survival. PVRi and mPAP are important objective parameters in the confirmation of the 
diagnosis and assessment of disease severity in PAH. Although reports on the prognostic 
value of mPAP and PVRi in PAH are inconsistent, several studies in paediatric PAH have shown 
a lack of significant prognostic value of mPAP and/or PVRi in these patients. In paediatric 
PAH, PACi and PSVi appeared to be stronger predictors of survival compared to mPAP and 
PVRi. Therefore, in the clinical situation PACi and PSVi can provide prognostic information ad-
ditional to conventional haemodynamic measurements, potentially improving goal-oriented 
treatment strategies.
In addition to PACi and PSVi, lower mPAP/mSAP, lower heart rate, and higher mSAP were 
associated with improved survival in our study. The association of mPAP/mSAP with survival 
is in congruence with previous reports, showing that high mPAP/mSAP is associated with 
poorer outcome in paediatric PAH.13,29 Since the associations of PACi and PSVi with survival 
were more stable in multivariate analysis than that of mSAP, mPAP/mSAP and heart rate, 
these pulsatile parameters seem to have a stronger prognostic value.
Heart rate and mSAP are affected by children’s age, which by itself is associated with outcome 
in paediatric PAH.12 Therefore age may partially explain their association with survival. In this 
study, the point estimates of the survival analyses remained numerically the same when cor-
rected for age. Therefore the associations of heart rate, PACi, PSVi, mSAP and mPAP/mSAP 
with survival appear age independent.
The association of heart rate with survival, previously reported in adult PAH, may provide 
important clinical advantages.30,31 Heart rate is a non-invasive, easily obtainable parameter 
suitable for multiple follow-up measurements in paediatric PAH. Therefore heart rate may 
potentially be a valuable parameter to assist in guiding therapy in paediatric PAH.
Heart rate may both determine and respond to stroke volume of the RV, LV or both combined 
and with that it is strongly related with PSVi. Despite this intimate relation, both parameters 
appeared independent predictors of survival in this study. Therefore both parameters may 
have complementary value in guiding treatment.
Study limitations
Our analyses were limited by the relatively small number of patients. Nevertheless, we found 
strong correlations between survival and the pulsatile haemodynamic variables. In paediatric 
pulmonary hypertension, a very rare disease, patient numbers and data regarding survival 
and prognostic parameters are extremely limited. Therefore this study contributes largely to 
the currently available data.
Furthermore, no paired case-control matching could be performed due to the low number of 
available control patients. Congenital heart defects associated with systemic to pulmonary 
shunts and low PVRi are currently corrected at an early age before PVRi rises, leaving virtually 
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no older patients with an important shunt and low PVR. Therefore a frequency matching 
approach was applied.
Conclusions
In conclusion, parameters of the pulsatile pulmonary circulation, such as PACi and PSVi, are 
associated with disease severity and predict survival in paediatric PAH, independent from 
conventional clinical prognostic parameters, such as PVRi. Therefore these parameters can 
be of complementary value to more conventional haemodynamic parameters in assessing 
disease severity, predicting survival and guiding treatment in paediatric PAH.
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